Press "Enter" to skip to content

Bayer stresses drug’s tolerability in bid for prostate cancer market

Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.

Also Read:   Deaths from China's coronavirus outbreak surpass deaths from SARS